The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).. Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010.. BESPONSA®(inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. BESPONSA is a type of medicine called an antibody-drug conjugate. BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells. The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment. B-cell precursor ALL is a type of cancer in which. About MYLOTARG (gemtuzumab ozogamicin) MYLOTARG is an investigational antibody-drug conjugate (ADC) comprised of the cytotoxic agent calicheamicin, attached to a monoclonal antibody (mAB) targeting CD33, an antigen expressed on the surface of myeloblasts in more than 90 percent of AML patients. 4,5,6 When MYLOTARG binds to the CD33 antigen on the cell surface it is absorbed into the cell and .